Market Size of MEA Bladder Cancer Therapeutics & Diagnostics Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Historical Data Period | 2019 - 2022 |
CAGR | 5.60 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
MEA Bladder Cancer Therapeutics & Diagnostics Market Analysis
The bladder cancer therapeutics and diagnostics market will witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing innovation in drug development. Based on the data from the International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. In countries in the Middle East and Africa (MEA) region like the United Arab Emirates (UAE), the bladder cancer is 8th most common type of cancer, as per Globocan 2018 data.
In recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developing regions such as Middle East and Africa. Also, the rise of different therapies such as immunotherapy in cancer treatment has rekindled interest among eligible patients as it is a recently developed treatment modality, and has lower side effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management.
Hence, the increasing awareness about bladder cancer and related therapies, the Middle East and Africa bladder cancer therapeutics and diagnostics market is expected to grow in the coming future.